Literature DB >> 22531786

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Kern Rei Chng1, Cheng Wei Chang, Si Kee Tan, Chong Yang, Shu Zhen Hong, Noel Yan Wei Sng, Edwin Cheung.   

Abstract

Transcriptional corepressors are frequently aberrantly over-expressed in prostate cancers. However, their crosstalk with the Androgen receptor (AR), a key player in prostate cancer development, is unclear. Using ChIP-Seq, we generated extensive global binding maps of AR, ERG, and commonly over-expressed transcriptional corepressors including HDAC1, HDAC2, HDAC3, and EZH2 in prostate cancer cells. Surprisingly, our results revealed that ERG, HDACs, and EZH2 are directly involved in androgen-regulated transcription and wired into an AR centric transcriptional network via a spectrum of distal enhancers and/or proximal promoters. Moreover, we showed that similar to ERG, these corepressors function to mediate repression of AR-induced transcription including cytoskeletal genes that promote epithelial differentiation and inhibit metastasis. Specifically, we demonstrated that the direct suppression of Vinculin expression by ERG, EZH2, and HDACs leads to enhanced invasiveness of prostate cancer cells. Taken together, our results highlight a novel mechanism by which, ERG working together with oncogenic corepressors including HDACs and the polycomb protein, EZH2, could impede epithelial differentiation and contribute to prostate cancer progression, through directly modulating the transcriptional output of AR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531786      PMCID: PMC3380210          DOI: 10.1038/emboj.2012.112

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

1.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

Review 3.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 4.  Androgen receptor corepressors and prostate cancer.

Authors:  Craig J Burd; Lisa M Morey; Karen E Knudsen
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

5.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.

Authors:  J Yu; Q Cao; J Yu; L Wu; A Dallol; J Li; G Chen; C Grasso; X Cao; R J Lonigro; S Varambally; R Mehra; N Palanisamy; J Y Wu; F Latif; A M Chinnaiyan
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

6.  CENTDIST: discovery of co-associated factors by motif distribution.

Authors:  Zhizhuo Zhang; Cheng Wei Chang; Wan Ling Goh; Wing-Kin Sung; Edwin Cheung
Journal:  Nucleic Acids Res       Date:  2011-05-20       Impact factor: 16.971

Review 7.  The epithelial-mesenchymal transition: new insights in signaling, development, and disease.

Authors:  Jonathan M Lee; Shoukat Dedhar; Raghu Kalluri; Erik W Thompson
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539

8.  Role of vinculin in regulating focal adhesion turnover.

Authors:  Ruth M Saunders; Mark R Holt; Lisa Jennings; Deborah H Sutton; Igor L Barsukov; Andrey Bobkov; Robert C Liddington; Eileen A Adamson; Graham A Dunn; David R Critchley
Journal:  Eur J Cell Biol       Date:  2006-04-03       Impact factor: 4.492

9.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

10.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.

Authors:  Charles E Massie; Boris Adryan; Nuno L Barbosa-Morais; Andy G Lynch; Maxine G Tran; David E Neal; Ian G Mills
Journal:  EMBO Rep       Date:  2007-08-17       Impact factor: 8.807

View more
  74 in total

1.  Class I lysine deacetylases facilitate glucocorticoid-induced transcription.

Authors:  Vineela Kadiyala; Nina M Patrick; Wana Mathieu; Rosa Jaime-Frias; Naruekamol Pookhao; Lingling An; Catharine L Smith
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

Review 2.  Minireview: Conversing with chromatin: the language of nuclear receptors.

Authors:  Simon C Biddie; Sam John
Journal:  Mol Endocrinol       Date:  2013-01-01

3.  A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.

Authors:  Feng Sun; Inthrani R Indran; Zhi Wei Zhang; M H Eileen Tan; Yu Li; Z L Ryan Lim; Rui Hua; Chong Yang; Fen-Fen Soon; Jun Li; H Eric Xu; Edwin Cheung; Eu-Leong Yong
Journal:  Carcinogenesis       Date:  2015-04-23       Impact factor: 4.944

4.  The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Authors:  Shu-Ting Chen; Maiko Okada; Ryuichiro Nakato; Kosuke Izumi; Masashige Bando; Katsuhiko Shirahige
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

5.  Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs.

Authors:  Päivi Pihlajamaa; Biswajyoti Sahu; Lauri Lyly; Viljami Aittomäki; Sampsa Hautaniemi; Olli A Jänne
Journal:  EMBO J       Date:  2014-01-22       Impact factor: 11.598

6.  Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Shuichi Tsutsumi; Tetsuya Fujimura; Satoru Takahashi; Yukio Homma; Tomohiko Urano; Hiroyuki Aburatani; Satoshi Inoue
Journal:  Mol Endocrinol       Date:  2014-12

7.  BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.

Authors:  Joanna K Lempiäinen; A B M Kaiser Manjur; Marjo Malinen; Kirsi Ketola; Einari A Niskanen; Jorma J Palvimo
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

10.  Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.

Authors:  Roberta Ciarapica; Elena Carcarino; Laura Adesso; Maria De Salvo; Giorgia Bracaglia; Pier Paolo Leoncini; Alessandra Dall'agnese; Federica Verginelli; Giuseppe M Milano; Renata Boldrini; Alessandro Inserra; Stefano Stifani; Isabella Screpanti; Victor E Marquez; Sergio Valente; Antonello Mai; Pier Lorenzo Puri; Franco Locatelli; Daniela Palacios; Rossella Rota
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.